Abstract
The serotonin system exerts its effects on the CNS and many peripheral systems. Of the 14 serotonin receptors, the 5-HT7 receptor is the most recently discovered. The 5-HT7 receptor has been shown to be involved in stress reduction, depression, and nociceptive control. Despite the 20 years since the discovery of 5-HT7R, there are still few truly selective ligands. Two of the common scaffolds for 5-HT7R ligands are long chain arylpiperazines (LCAPs) and sulfonamide containing compounds. This review focuses on recently developed (2014-2016) 5-HT7R ligands, their selectivity for the receptor, and suggests the possible new pharmacophore models for these ligands.
Original language | English |
---|---|
Pages (from-to) | 552-560 |
Number of pages | 9 |
Journal | Mini-Reviews in Medicinal Chemistry |
Volume | 18 |
Issue number | 7 |
DOIs | |
State | Published - Apr 1 2018 |
Bibliographical note
Publisher Copyright:© 2018 Bentham Science Publishers.
Funding
Funders | Funder number |
---|---|
National Center for Complementary and Integrative Health | R15AT008060 |
Keywords
- 5-HT7
- Arylpiperazine
- CNS
- Drug design
- Pharmacophore
- Serotonin
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology
- Drug Discovery
- Cancer Research